• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Osteosarcoma - Pipeline Review, H1 2013 Product Image

Osteosarcoma - Pipeline Review, H1 2013

  • ID: 2526464
  • April 2013
  • 74 pages
  • Global Markets Direct

Osteosarcoma – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Osteosarcoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteosarcoma. Osteosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Osteosarcoma.
- A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Osteosarcoma Overview
Therapeutics Development
An Overview of Pipeline Products for Osteosarcoma
Osteosarcoma Therapeutics under Development by Companies
Osteosarcoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Osteosarcoma Therapeutics – Products under Development by Companies
Osteosarcoma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Osteosarcoma Therapeutics Development
Shionogi & Co., Ltd.
Merck & Co., Inc.
Oncolytics Biotech Inc.
Simcere Pharmaceutical Group
Med Discovery SA
Aileron Therapeutics, Inc.
Hawthorn Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc.
Epeius Biotechnologies Corporation
Osteosarcoma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
cisplatin reformulation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDRG-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pelareorep - Drug Profile
Product Description
Mechanism of Action
R&D Progress
robatumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMTP-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rexin-G - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bevacizumab + [cisplatin] + [doxorubicin] + [etoposide] + [ifosfamide] + [methotrexate] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Angiotensin 1-7 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sirolimus + [cyclophosphamide] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Reolysin + [cisplatin] + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HU14.18K322A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PBF Peptide Vaccine + [interferon alpha] + [IFA] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Haw mAb-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WT-1 Immunotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endostatin + [cisplatin] + [ifosfamide] + [methotrexate] + [pirarubicin] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous Dendritic Cell Vaccine + [decitabine] + [imiquimod] - Drug Profile
Product Description
Mechanism of Action
R&D Progress
p53 Transcription Factor Derived Stapled Peptides - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MBC-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs Targeting Thymidylate Synthase And Dihydrofolate Reductase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
De-Methylated Derivatives Of Colchicine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide Cocktail Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Osteosarcoma Therapeutics – Drug Profile Updates
Osteosarcoma Therapeutics – Discontinued Products
Osteosarcoma Therapeutics - Dormant Products
Osteosarcoma – Product Development Milestones
Featured News & Press Releases
Jun 24, 2011: PCI Biotech Announces Main Results Of Full Phase I/II Study Of Amphinex
Apr 27, 2011: Oncolytics Biotech Announces Start Of Conformity Testing With SAFC
Oct 12, 2009: Clinical Remissions In Three Otherwise Intractable Cancers Signal The Progress Of Targeted Genetic Medicine
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Osteosarcoma, H1 2013
Products under Development for Osteosarcoma – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Shionogi & Co., Ltd., H1 2013
Merck & Co., Inc., H1 2013
Oncolytics Biotech Inc., H1 2013
Simcere Pharmaceutical Group, H1 2013
Med Discovery SA, H1 2013
Aileron Therapeutics, Inc., H1 2013
Hawthorn Pharmaceuticals, Inc., H1 2013
Eleison Pharmaceuticals, Inc., H1 2013
Epeius Biotechnologies Corporation, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Osteosarcoma Therapeutics – Drug Profile Updates
Osteosarcoma Therapeutics – Discontinued Products
Osteosarcoma Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Osteosarcoma, H1 2013
Products under Development for Osteosarcoma – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Discovery and Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013 35

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos